| Basics |
Syros Pharmaceuticals, Inc.
Syros Pharmaceuticals Inc is a biopharmaceutical company engaged in the understanding of the region of the genome controlling the activation and repression of genes. The companies lead candidates are SY-1425 and SY-1365.
|
| IPO Date: |
June 30, 2016 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Activated in VL: |
False |
| Average Daily Range |
| Avg Daily Range: |
$0.27 | 4.18%
|
| Avg Daily Range (30 D): |
$0.01 | 74.07%
|
| Avg Daily Range (90 D): |
$0.01 | 58.33%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.01M |
| Avg Daily Volume (30 D): |
.03M |
| Avg Daily Volume (90 D): |
.11M |
| Trade Size |
| Avg Trade Size (Sh.): |
370 |
| Avg Trade Size (Sh.) (30 D): |
797 |
| Avg Trade Size (Sh.) (90 D): |
1,499 |
| Institutional Trades |
| Total Inst.Trades: |
229 |
| Avg Inst. Trade: |
$1.68M |
| Avg Inst. Trade (30 D): |
$2M |
| Avg Inst. Trade (90 D): |
$2M |
| Avg Inst. Trade Volume: |
.03M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.85M |
| Avg Closing Trade (30 D): |
$M |
| Avg Closing Trade (90 D): |
$M |
| Avg Closing Volume: |
24.57K |
|
|
| Financials |
| |
TTM |
Q3 2024 |
Q2 2024 |
|
Basic EPS
|
$-3.07
|
$-.16
|
$-.59
|
|
Diluted EPS
|
$-3.07
|
$-.16
|
$-.59
|
|
Revenue
|
$ .39M
|
$ M
|
$ M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -97.82M
|
$ -6.4M
|
$ -23.33M
|
|
Operating Income / Loss
|
$ -111.66M
|
$ -26.18M
|
$ -27.42M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -54.91M
|
$ -20.69M
|
$ -4.56M
|
|
PE Ratio
|
|
|
|
|
|
|
